<DOC>
	<DOCNO>NCT00753909</DOCNO>
	<brief_summary>This trial evaluate efficacy safety paclitaxel , carboplatin bevacizumab combination , administer biweekly , patient pretreated , advance non small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin Plus Bevacizumab Pretreated , Advanced Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description>The addition bevacizumab paclitaxel plus carboplatin 1st line treatment patient advance metastatic non small cell lung cancer ( NSCLC ) provide survival benefit . There patient NSCLC receive bevacizumab relapse 1st and/or 2nd line therapy . The evaluation bevacizumab plus chemotherapy patient justified . The combination paclitaxel carboplatin , administer every two week , favorable toxicity profile . This study evaluate addition bevacizumab biweekly regimen paclitaxel carboplatin 2nd 3rd line therapy NSCLC</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm , unresectable locally advanced ( stage IIIB ) metastatic ( stage IV ) nonsquamous NSCLC Nonsquamous histologic type At least one two previous chemotherapy regimen advance metastatic NSCLC Measurable disease , define least 1 bidimensionally measurable lesion ≥ 20 X 10 mm . Age ≥ 18 year Performance status ( WHO ) 02 Life expectancy least 12 week Adequate bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥ 100,000/mm3 , Hgb ≥ 9 g/dL ) , liver ( Bilirubin ≤ 1.5 upper normal limit , SGOT/SGPT ≤ 2.5 upper normal limit absence liver metastases ≤ 5 upper normal limit presence liver metastasis ) , renal function ( Creatinine ≤ 1,5 upper normal limit ) Patients must able understand nature study Written inform consent Previous therapy paclitaxel combination carboplatin Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer Pregnant lactate woman Any serious , uncontrolled comorbidity investigator 's judgment Uncontrolled infection Any sustain chronic toxicity &gt; grade 2 accord NCI CTCAE ( version 3.0 ) Symptomatic neuropathy &gt; grade 2 accord NCI CTCAE ( version 3.0 ) Brain metastasis , except radiate asymptomatic Radiotherapy within previous 4 week Previous radiotherapy measurable lesion Proteinuria ≥ 500 mgr protein daily Hemoptysis &gt; 10 cc per event Clinically significant hematemesis Centrally locate lesion contact major vessel Pulmonary lesion cavitation Documented hemorrhagic diathesis coagulation disorder Cardiovascular disease ( class IIIV NYHA congestive heart failure , myocardial infarction within previous 4 month , unstable angina , LVEF &lt; normal , ventricular arrhythmia , uncontrolled hypertension ) Thrombotic event within previous 6 month Concurrent use aspirin &gt; 325 mgr daily , low molecular weight heparin therapeutic dose , warfarin acenocoumarol , nonsteroid antiinflammatory agent Concurrent treatment anticancer drug Major surgical procedure within previous 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>